216 related articles for article (PubMed ID: 33781364)
1. Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Lafuente-Romero A; Rodriguez Ogando A
Cardiol Young; 2021 Sep; 31(9):1513-1515. PubMed ID: 33781364
[TBL] [Abstract][Full Text] [Related]
2. Single-Center Experience Using Selexipag in a Pediatric Population.
Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
[TBL] [Abstract][Full Text] [Related]
3. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
4. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
5. Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L; Wacker J; Beghetti M; Lador F
Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
[TBL] [Abstract][Full Text] [Related]
6. Selexipag for the treatment of pulmonary arterial hypertension.
Sharma K
Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
[TBL] [Abstract][Full Text] [Related]
7. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA; Chin KM
Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of selexipag for the treatment of pulmonary hypertension.
Panagiotidou E; Boutou A; Pitsiou G
Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
[TBL] [Abstract][Full Text] [Related]
9. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
10. Selexipag: A Review in Pulmonary Arterial Hypertension.
Duggan ST; Keam SJ; Burness CB
Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
[TBL] [Abstract][Full Text] [Related]
11. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
12. Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome: First Report.
El-Kersh K; Suliman S; Smith JS
Am J Ther; 2018; 25(6):e714-e715. PubMed ID: 29521655
[No Abstract] [Full Text] [Related]
13. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N
Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
16. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
Demerouti EA; Karyofyllis P; Apostolopoulou SC
Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
[TBL] [Abstract][Full Text] [Related]
17. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
[TBL] [Abstract][Full Text] [Related]
18. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Sardana M; Moll M; Farber HW
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
